Allucent is a CRO which has overseen many therapeutics through to FDA approval.
How do small biotechs bursting with innovation leverage the toolbox of big pharma?
Enter Allucent, led by CEO Paula Brown Stafford, who are turbocharging drug developers worldwide!
I had the pleasure of catching up with Paula at JPM Week 2025.
Yours sincerely,
Dr. Adil Ali
“We can regulate any gene, anywhere,” says CEO Dr. Amber Salzman, whose Epicrispr team is pioneering epigenetic editing - a precise, non-cutting approach - to transform neuromuscular disease treatment through durable, targeted control of gene activity.
With a median progression-free survival nearing four years in ROS1 lung cancer, Nuvation Bio’s breakthrough therapy signals a turning point for precision oncology - validating Dr. David Hung’s patient-first vision.
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
